Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

what they have been doing is the standard clinical trial approach to any new medication. They have now shown safety for a drug with a short half life given once weekly

Whether it will be safe when given at other doses is NOT known.

Nor is there any data on efficacy that is meaningful.

There is the thymoma pt who is doing well. There are some elevations in p21 in some pts. This is NOT efficacy

There is no convincing data on efficacy and of course this awaits phase 2

Promising drugs fail in phase 2's all the time and Kevetrin may fail as well